Prior Biologic Therapy

Cross-source consensus on Prior Biologic Therapy from 1 sources and 76 claims.

1 sources · 76 claims

How it works

Comparisons

Background

Evidence quality

Other

Highlighted claims

In the subset of patients receiving both omalizumab and benralizumab, the percentage with prior HES-related biologic therapy in the preceding 12 months was corrected from 1.5% to 3.0%. — Brazilian elimination of mother-to-child HIV transmission: lessons for large-scale global health systems
Omalizumab was used alongside benralizumab in a subgroup of 67 trial participants. — Brazilian elimination of mother-to-child HIV transmission: lessons for large-scale global health systems
In the omalizumab and benralizumab subgroup (n=67), 2 patients had received prior HES-related biologic therapy in the preceding 12 months, representing 3.0% of that subgroup. — Brazilian elimination of mother-to-child HIV transmission: lessons for large-scale global health systems
The original percentage error arose from dividing against the total population (N=133) rather than the subgroup size (n=67). — Brazilian elimination of mother-to-child HIV transmission: lessons for large-scale global health systems
The percentage of patients in the benralizumab subgroup with prior HES-related biologic therapy was corrected from 1.5% to 3.0%. — Brazilian elimination of mother-to-child HIV transmission: lessons for large-scale global health systems
The original percentage error arose from calculating relative to the total population (2/133) rather than the subgroup size (2/67). — Brazilian elimination of mother-to-child HIV transmission: lessons for large-scale global health systems
Two patients in the benralizumab+omalizumab subgroup received prior HES-related biologic therapy in the preceding 12 months, correctly representing 3.0% of the subgroup rather than the originally published 1.5%. — Brazilian elimination of mother-to-child HIV transmission: lessons for large-scale global health systems
The original percentage was miscalculated by dividing by the total trial population (133) instead of the relevant subgroup size (67). — Brazilian elimination of mother-to-child HIV transmission: lessons for large-scale global health systems
The percentage of benralizumab-group patients with prior HES-related biologic therapy in the preceding 12 months was corrected from 1.5% to 3.0%. — Brazilian elimination of mother-to-child HIV transmission: lessons for large-scale global health systems
Two patients in the omalizumab and benralizumab subset had prior HES-related biologic therapy within the preceding 12 months. — Brazilian elimination of mother-to-child HIV transmission: lessons for large-scale global health systems